Triage DD of short bowel syndrome assets

Challenge:

For a mid-size European pharma company thinking of entering a new therapeutic area, we conducted ‘Triage’ level due diligence which focused only on publicly available information for three assets being developed for a specific indication. 

Solution:

Using publicly-available information about each program, together with an analysis of the landscape in the particular indication we provided a high-level assessment in the following areas:

• Scientific rationale of the mechanism of action in the target indication
• Strength of proof-of-concept data
• Summary of regulatory status e.g., designations
• Market opportunity including competitive landscape and differentiation

We conducted the entire assessment within a one week timeframe.

Due Diligence Services

Alacrita's due diligence experts have conducted over 200 major assignments for large pharma, biotech, universities and investors, underpinned by our ability to ensure each due diligence exercise is supported by individuals with the precise expertise required for a complete, thorough and accurate assessment.